Evidence map›Paper›PMID 37900679›Full record

ArticleFrontiers in pediatrics2023

Effect of autologous umbilical cord blood transfusion in the development of retinopathy of prematurity: randomized clinical trial - study protocol.

Laura Torrejon-Rodriguez, Alejandro Pinilla-Gonzalez, Inmaculada Lara Cantón, Abel Albiach-Delgado, Mari Merce Cascant-Vilaplana, María Cernada, Julia Kuligowski, Maria Pilar Solves Alcaina, Inés Gómez, Maximo Vento and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07502781 (Multicenter, Randomized, Double-Blind Pilot Clinical Trial Evaluating the Impact of Transfusion With Heterologous Cord Blood-Derived Red Blood Cells Versus Adult Red Blood Cells in Extremely Premature Infants), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07502781 nanot yet recruitingnot on this mapstarted 2027, after this paper: background citation

Multicenter, Randomized, Double-Blind Pilot Clinical Trial Evaluating the Impact of Transfusion With Heterologous Cord Blood-Derived Red Blood Cells Versus Adult Red Blood Cells in Extremely Premature Infants

TypeinterventionalSponsorHospital Clinic of BarcelonaRan2027 to 2029Enrolled176ConditionsExtremely Premature Infant, Anemia Neonatal, Blood Transfusion, Umbilical Cord BloodArmsCord Blood Red Blood Cells, Standard Adult Donor Red Blood Cells
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Involving neonatal hematology and transfusion medicine in global efforts to eliminate severe retinopathy of prematurity.Journal of perinatology : official journal of the California Perinatal Association · 2025
    Review
  5. Article
  6. Article
  7. [Progress in the clinical application of cord blood transfusion in neonates].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  8. Observational
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Laura Torrejon-RodriguezDepartment of Neonatology, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
Alejandro Pinilla-GonzalezDepartment of Neonatology, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
Inmaculada Lara CantónDepartment of Neonatology, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
Abel Albiach-DelgadoNeonatal Research Group, Hospital Universitario y Politécnico La Fe (HULAFE), Valencia, Spain.
Mari Merce Cascant-VilaplanaNeonatal Research Group, Hospital Universitario y Politécnico La Fe (HULAFE), Valencia, Spain.
María CernadaDepartment of Neonatology, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
Julia KuligowskiNeonatal Research Group, Hospital Universitario y Politécnico La Fe (HULAFE), Valencia, Spain.
Maria Pilar Solves AlcainaDepartment of Hematology, Hospital Universitario y Politécnico La Fe (HULAFE), Valencia, Spain.
Inés GómezDepartment of Hematology, Hospital Universitario y Politécnico La Fe (HULAFE), Valencia, Spain.
Maximo VentoNeonatal Research Group, Hospital Universitario y Politécnico La Fe (HULAFE), Valencia, Spain.
Marta Aguar CarrascosaDepartment of Neonatology, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
Hospital Universitari i Politècnic La Fe · ESInstituto de Investigación Sanitaria La Fe · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Currently, the treatment of anemia in preterm infants is based on packed red blood cell (RBC) transfusions from adult donors. Oxygen (O2) is mainly transported to the tissues bound to hemoglobin (Hb). In extremely low gestational age neonates (ELGANs), fetal hemoglobin (HbF), which has a higher affinity for O2, represents up to 95% of circulating hemoglobin. During the first month of life, the majority of ELGANs will require an adult-donor RBC transfusion causing HbF levels to rapidly drop. HbA releases 50% more oxygen in peripheral tissues than HbF. Increased release of O2 in the retina is one of the main factors related to the development of retinopathy of prematurity (ROP). Collecting umbilical cord blood and using autologous umbilical cord whole blood (UCB) transfusions would contribute to maintaining physiological HbF concentrations in newborns and avoid oxygen-in-excess derived damage. Methods: This is a randomized, double-blinded, multicenter clinical trial. ELGANs ≤28 weeks of gestational age will be randomized 1:1 to receive an autologous umbilical cord blood transfusion (intervention arm) or standard transfusion of packed RBC from an adult donor (control arm) to assess ROP development. Assuming a 50% reduction in ROP incidence, 134 patients (67 per group) will be recruited. When blood transfusion is indicated, the Blook Bank will supply UCB or RCB according to the patient's group. The primary endpoint is the incidence of any ROP. Secondary endpoints are assessessment of treatment safety, results of biomarkers related to ROP and its chronology, and urine oxidative stress markers. In addition, the cellular composition of umbilical cord blood and its relationship with prematurity-related pathologies will be analyzed. All patients will be followed-up to 24 months of corrected age to evaluate their neurodevelopment. Discussion: ROP is a major cause of irreversible blindness in preterm newborns. Transfusions with adult donor blood can lead to complications, including ROP. UCB transfusions offer advantages by maintaining physiological HbF levels and potentially optimizing postnatal development. Moreover, autologous UCB transfusion could reduce risks associated with heterologous blood products, although volume collection remains challenging. UCB contains growth factors and progenitor cells that may impact ROP.

Indexed as

fetal hemoglobinprematurityretinopathy of prematuritytransfusionumbilical cord blood

Identifiers

PMID37900679
PMCPMC10602804
OpenAlexW4387569549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.